

July 2024

Vitrafy Life Sciences announces the appointment of Dr David Goad as its Chief Technology Officer

Vitrafy is delighted to share that Dr David Goad will join the company as Chief Technology Officer, commencing on 1 August 2024.

David brings over 25 years' experience in developing innovative technology solutions. He was most recently the Chief Technology Officer and Head of Advisory at IBM Consulting ANZ. He is also a Microsoft Regional Director (a small team of industry experts selected by Microsoft to provide advice on the companies' product roadmaps and business strategy).

David's experience includes Chief Architect – Automation & Innovation at University of Sydney; Head of Strategy at the Fortune 500 company Insight; Managing Director at eSavvy which was a cloud-based systems integrator and Director for Microsoft Asia Pacific.

David has a PhD in Artificial Intelligence and the Internet of Things from the University of Sydney; a MBA in Finance and a Bachelor of Chemical Engineering and Management from McMaster University in Canada and a Bachelor of Arts from York University in Canada. He holds over 20 technical certifications across a number of technology platforms.

In 2023, David was ranked one of the Top 10 CTO's in APAC by Technology Magazine and number 2 in Australia.

David will significantly enhance the Vitrafy team that has been developing and commercialising LifeChain™ and we look forward to his contribution.

For media enquiries contact:
Kate Munnings
CEO Vitrafy Life Sciences
Mobile: 0419661117
Email: kmunnings@vitrafy.com

About Vitrafy Life Sciences

Vitrafy is an Australian biotechnology company that has developed an innovative software platform LifeChain™, and accompanying smart medical devices which materially improve the quality of cryopreserved biological materials – setting a new global standard for healthcare treatments;
Preserving Life.